See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
NATO
Social Media
New York State Politics
Donald Trump
European Union
Heatwaves
Infrastructure
Natural Disasters
Amazon
Stock Markets
Work
Published • loading... • Updated

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

Summary by onclive.com
Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
onclive.comonclive.com

Durvalumab Plus Tremelimumab and Trastuzumab Yields Clinical Activity in Trastuzumab-Resistant HER2+ Breast Cancer

Durvalumab plus tremelimumab and trastuzumab produced responses in trastuzumab-resistant, HER2-positive advanced breast cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

onclive.com broke the news in on Friday, May 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal